Head and Neck Squamous Cell Carcinoma Market Analysis

Distribution Channel (Hospital Pharmacies, Retail, Online Pharmacies)

The global head and neck squamous cell carcinoma (HNSCC) market is segmented and analyzed for demand and supply by distribution channel into hospital pharmacies, retail, and online pharmacies. Out of these three types of segments, the hospital pharmacies segment is estimated to gain the largest market share of about 55% in the year 2037. The growth of the segment can be attributed to the increasing number of cancer patients visiting the hospital for treatments, and therefore they need HNSCC drugs at the hospital premises. For instance, from 2015 to 2019, the number of cancer patients who visited the emergency department in Korea reached around 1,473,120. Nearly 55% of cancer-related ED visits ended in hospitalization, with 6% in ICU, and 10% died in the hospitals. On the other hand, several cancer treatment drugs are restricted for sale on online platforms or even to retail pharmacy outlets. As a result, these restricted drugs are available only in hospital pharmacies, which is anticipated to drive the growth of the segment during the forecast period.

Drug Class (Immunotherapy, Chemotherapy, Targeted Therapy)

The global head and neck squamous cell carcinoma (HNSCC) market is also segmented and analyzed for demand and supply by drug class into immunotherapy, chemotherapy, and targeted therapy. Amongst these three segments, the immunotherapy segment is expected to garner a significant share of around 60% in the year 2037. The growth of the segment can be attributed to the significantly growing awareness among people regarding the effectiveness and advantages of cancer immunotherapy over chemotherapy is anticipated to fuel the segment’s growth over the forecast period. Furthermore, the surge in drug trials, coupled with the augmenting ratio of novel drugs approval from the authorities such as the FDA and EMA is also estimated to drive the segment growth further during the projected time frame. For instance, Nivolumab (Opdivo) and Pembrolizumab (Keytruda), are two PD-L1 inhibitors, licensed for the treatment of patients with head and neck cancer. Whilst, Dostarlimab (Jemperli) is under phase II clinical trials for head and neck squamous cell carcinoma that has progressed or resurfaced. On the other hand, the chemotherapy segment is projected to witness a notable CAGR during the forecast period, owing to the rising adoption of chemotherapy along with radiation therapy amongst cancer patients worldwide. Moreover, the escalating usage of chemotherapy with the combination of other drugs and therapy has been delivering good outcomes. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.

Our in-depth analysis of the global market includes the following segments: